SMAD6
Mothers against decapentaplegic homolog 6
Also known as: HsT17432, MADH6, MADH7, SMAD6_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O43541
- Gene
- SMAD6
- Ensembl
- ENSG00000137834
- Chromosome
- 15
- Canonical length
- 496 aa
- Protein class
- Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors
- Subcellular location
- Nucleoplasm,Nuclear bodies,Primary cilium,Basal body,Cytosol
OverviewNCBI Gene
The protein encoded by this gene belongs to the SMAD family of proteins, which are related to Drosophila 'mothers against decapentaplegic' (Mad) and C. elegans Sma. SMAD proteins are signal transducers and transcriptional modulators that mediate multiple signaling pathways. This protein functions in the negative regulation of BMP and TGF-beta/activin-signalling. Multiple transcript variants have been found for this gene.[provided by RefSeq, Sep 2014]
Canonical amino-acid sequenceUniProt
496 residues, UniProt reviewed canonical sequence.
>O43541|SMAD6
1 MFRSKRSGLV RRLWRSRVVP DREEGGSGGG GGGDEDGSLG SRAEPAPRAR EGGGCGRSEV
61 RPVAPRRPRD AVGQRGAQGA GRRRRAGGPP RPMSEPGAGA GSSLLDVAEP GGPGWLPESD
121 CETVTCCLFS ERDAAGAPRD ASDPLAGAAL EPAGGGRSRE ARSRLLLLEQ ELKTVTYSLL
181 KRLKERSLDT LLEAVESRGG VPGGCVLVPR ADLRLGGQPA PPQLLLGRLF RWPDLQHAVE
241 LKPLCGCHSF AAAADGPTVC CNPYHFSRLC GPESPPPPYS RLSPRDEYKP LDLSDSTLSY
301 TETEATNSLI TAPGEFSDAS MSPDATKPSH WCSVAYWEHR TRVGRLYAVY DQAVSIFYDL
361 PQGSGFCLGQ LNLEQRSESV RRTRSKIGFG ILLSKEPDGV WAYNRGEHPI FVNSPTLDAP
421 GGRALVVRKV PPGYSIKVFD FERSGLQHAP EPDAADGPYD PNSVRISFAK GWGPCYSRQF
481 ITSCPCWLEI LLNNPRLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SMAD6 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.46
- Highest tissue expression
- 29 nTPM
Expression across tissuesHPA
Tissue
- heart muscle: 29 nTPM
- lung: 26 nTPM
- blood vessel: 16 nTPM
- thyroid gland: 15 nTPM
- adipose tissue: 9 nTPM
- kidney: 8.4 nTPM
Single-cell type
- podocytes: 219 nCPM
- vascular endothelial cells: 148 nCPM
- adipocytes: 127 nCPM
- pituitary stem cells: 59 nCPM
- choroid plexus epithelial cells: 52 nCPM
- microglia: 46 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- choroid plexus: 18 nTPM
- medulla oblongata: 16 nTPM
- thalamus: 14 nTPM
- pons: 12 nTPM
- midbrain: 11 nTPM
- amygdala: 10 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about SMAD6.
Disease | AllUniProt
Conditions SMAD6 is implicated in, by any mechanism.
- Aortic valve disease 2 (AOVD2) MIM:614823
- Craniosynostosis 7 (CRS7) MIM:617439
- Radioulnar synostosis, non-syndromic (RUS) MIM:179300
Disease | GeneticClinVar
84 pathogenic / likely-pathogenic of 1,331 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Radioulnar synostosis
- Aortic valve disease 2
- Craniosynostosis 7
- Radioulnar synostosis, nonsyndromic, susceptibility to
- Inborn genetic diseases
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.98
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.59
- DepMap mean gene effect
- -0.03
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- anatomical structure morphogenesis
- aorta development
- aortic valve morphogenesis
- BMP signaling pathway
- cell differentiation
- cell-substrate adhesion
- coronary vasculature development
- fat cell differentiation
- immune response
- mitral valve morphogenesis
- negative regulation of activin receptor signaling pathway
- negative regulation of apoptotic process
- negative regulation of BMP signaling pathway
- negative regulation of cell population proliferation
- negative regulation of ossification
- negative regulation of osteoblast differentiation
- negative regulation of SMAD protein signal transduction
- negative regulation of transforming growth factor beta receptor signaling pathway
- outflow tract septum morphogenesis
- positive regulation of miRNA transcription
- pulmonary valve morphogenesis
- regulation of transcription by RNA polymerase II
- response to estrogen
- response to laminar fluid shear stress
- response to lipopolysaccharide
- SMAD protein signal transduction
- ureteric bud development
- ventricular septum development
- zygotic specification of dorsal/ventral axis
Molecular functions
- chromatin binding
- co-SMAD binding
- I-SMAD binding
- identical protein binding
- metal ion binding
- protein sequestering activity
- R-SMAD binding
- transcription cis-regulatory region binding
- transcription regulator inhibitor activity
- type I activin receptor binding
- type I transforming growth factor beta receptor binding
- ubiquitin protein ligase binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of SMAD6 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SMAD6 as an antibody target. Whether an autoantibody or antibody against SMAD6 could matter depends on whether native SMAD6 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SMAD6 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label SMAD6 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...